Design Therapeutics (DSGN) Receivables - Other (2020 - 2026)

Design Therapeutics' Receivables - Other history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 29.75% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 29.75% YoY), while the FY2025 annual figure was $1.7 million, up 32.78% from the prior year.
• Receivables - Other came in at $1.8 million for Q1 2026 at Design Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.8 million in Q1 2026 to a low of $100000.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.3 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other surged 1487.23% in 2022 and slipped 16.17% in 2025, its largest moves.
• Design Therapeutics' Receivables - Other stood at $1.1 million in 2022, then grew by 28.43% to $1.4 million in 2023, then fell by 11.8% to $1.3 million in 2024, then jumped by 32.78% to $1.7 million in 2025, then rose by 8.71% to $1.8 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.8 million, $1.7 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison